Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia
| Autor: | VA Craig, David J. Curtis, Jenny A. Orchard, H. Myint, J. A. Copplestone, Archie G. Prentice, M. D. Hamon, David Oscier, Terry J. Hamblin |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Male Hemolytic anemia Exacerbation medicine.medical_treatment Chronic lymphocytic leukemia Antineoplastic Agents hemic and lymphatic diseases medicine Humans Aged Aged 80 and over Autoimmune disease Chemotherapy business.industry Hematology Middle Aged medicine.disease Haemolysis Leukemia Lymphocytic Chronic B-Cell Fludarabine Leukemia Immunology Female Anemia Hemolytic Autoimmune business Vidarabine medicine.drug |
| Zdroj: | British Journal of Haematology. 91:341-344 |
| ISSN: | 1365-2141 0007-1048 |
| DOI: | 10.1111/j.1365-2141.1995.tb05300.x |
| Popis: | We have treated 52 patients with chronic lymphocytic leukaemia (CLL) with fludarabine; 12 developed severe autoimmune haemolysis. Only three had a previous history of haemolytic anaemia. Six out of eight patients retreated with fludarabine after control of their haemolysis developed an exacerbation of the haemolytic anaemia. The cause of autoimmune phenomena in CLL is not known, but our findings reinforce the view that they are caused by a disturbance in immunoregulatory T cells. Fludarabine is a known suppressor of T-cell function. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text